cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation
Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).
The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
